Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisEric L. Simpson, Marius Ardeleanu, Thomas Bieber et al.|New England Journal of Medicine|2016Cited by 2k
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunityLam C. Tsoi, John J. Voorhees, Sarah L. Spain et al.|Nature Genetics|2012Cited by 1k
Epidermal Barrier Dysfunction in Atopic DermatitisMichael J. Cork, Simon Ward, Simon G. Danby et al.|Journal of Investigative Dermatology|2009Cited by 756
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*Andreas Wollenberg, Andrew Blauvelt, Emma Guttman‐Yassky et al.|British Journal of Dermatology|2020Cited by 590
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trialAmy S. Paller, Brad Shumel, Megan Hardin et al.|Journal of the American Academy of Dermatology|2020Cited by 385